268 related articles for article (PubMed ID: 27255136)
21. A survey of synthetic cannabinoid consumption by current cannabis users.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Subst Abus; 2014; 35(2):184-9. PubMed ID: 24821356
[TBL] [Abstract][Full Text] [Related]
22. [Short-and long-term effects of cannabinoids on memory, cognition and mental illness].
Sagie S; Eliasi Y; Livneh I; Bart Y; Monovich E
Harefuah; 2013 Dec; 152(12):737-41, 751. PubMed ID: 24483000
[TBL] [Abstract][Full Text] [Related]
23. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH
Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903
[TBL] [Abstract][Full Text] [Related]
24. Synthetic cannabinoid hyperemesis resulting in rhabdomyolysis and acute renal failure.
Argamany JR; Reveles KR; Duhon B
Am J Emerg Med; 2016 Apr; 34(4):765.e1-2. PubMed ID: 26422191
[TBL] [Abstract][Full Text] [Related]
25. The Pharmacologic and Clinical Effects of Illicit Synthetic Cannabinoids.
White CM
J Clin Pharmacol; 2017 Mar; 57(3):297-304. PubMed ID: 27610597
[TBL] [Abstract][Full Text] [Related]
26. Synthetic Cannabinoids.
Mills B; Yepes A; Nugent K
Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
[TBL] [Abstract][Full Text] [Related]
27. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.
Tait RJ; Caldicott D; Mountain D; Hill SL; Lenton S
Clin Toxicol (Phila); 2016; 54(1):1-13. PubMed ID: 26567470
[TBL] [Abstract][Full Text] [Related]
28. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.
Bassir Nia A; Medrano B; Perkel C; Galynker I; Hurd YL
J Psychopharmacol; 2016 Dec; 30(12):1321-1330. PubMed ID: 27462088
[TBL] [Abstract][Full Text] [Related]
29. Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
Abouchedid R; Ho JH; Hudson S; Dines A; Archer JR; Wood DM; Dargan PI
J Med Toxicol; 2016 Dec; 12(4):396-401. PubMed ID: 27456262
[TBL] [Abstract][Full Text] [Related]
30. Safety issues concerning the medical use of cannabis and cannabinoids.
Ware MA; Tawfik VL
Pain Res Manag; 2005; 10 Suppl A():31A-7A. PubMed ID: 16237480
[TBL] [Abstract][Full Text] [Related]
31. Neurological soft signs in non-psychotic patients with cannabis dependence.
Dervaux A; Bourdel MC; Laqueille X; Krebs MO
Addict Biol; 2013 Mar; 18(2):214-21. PubMed ID: 21054691
[TBL] [Abstract][Full Text] [Related]
32. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review.
Hobbs M; Kalk NJ; Morrison PD; Stone JM
Eur Neuropsychopharmacol; 2018 Dec; 28(12):1289-1304. PubMed ID: 30454908
[TBL] [Abstract][Full Text] [Related]
33. Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis.
Lamy FR; Daniulaityte R; Nahhas RW; Barratt MJ; Smith AG; Sheth A; Martins SS; Boyer EW; Carlson RG
Int J Drug Policy; 2017 Jun; 44():121-129. PubMed ID: 28578250
[TBL] [Abstract][Full Text] [Related]
34. Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity.
Anderson SAR; Oprescu AM; Calello DP; Monte A; Dayan PS; Hurd YL; Manini AF;
Pediatrics; 2019 Aug; 144(2):. PubMed ID: 31285395
[TBL] [Abstract][Full Text] [Related]
35. Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors.
Hindson SA; Andrews RC; Danson MJ; van der Kamp MW; Manley AE; Sutcliffe OB; Haines TSF; Freeman TP; Scott J; Husbands SM; Blagbrough IS; Anderson JLR; Carbery DR; Pudney CR
FEBS J; 2023 Jun; 290(12):3243-3257. PubMed ID: 36708234
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
Palamar JJ; Su MK; Hoffman RS
Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258
[TBL] [Abstract][Full Text] [Related]
37. Validation of the Prognostic Utility of the Electrocardiogram for Acute Drug Overdose.
Manini AF; Nair AP; Vedanthan R; Vlahov D; Hoffman RS
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28159815
[TBL] [Abstract][Full Text] [Related]
38. Narrative Review of the Pharmacodynamics, Pharmacokinetics, and Toxicities of Illicit Synthetic Cannabinoid Receptor Agonists.
Lea Houston M; Morgan J; Kelso C
Mini Rev Med Chem; 2024; 24(1):92-109. PubMed ID: 37190813
[TBL] [Abstract][Full Text] [Related]
39. Health Risk Behaviors With Synthetic Cannabinoids Versus Marijuana.
Clayton HB; Lowry R; Ashley C; Wolkin A; Grant AM
Pediatrics; 2017 Apr; 139(4):. PubMed ID: 28289138
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoid hyperemesis: marijuana puts patients in hot water.
Wallace D; Martin AL; Park B
Australas Psychiatry; 2007 Apr; 15(2):156-8. PubMed ID: 17464661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
